Abstract
We herein review experimental and theoretical approaches widely applied to delineation of the differences in substrate specificities between human and parasite phosphoribosyltransferases (PRTases), the latter of which are key targets for treatment of diseases caused by parasites. Standard Molecular Dynamics (MD) simulations have been applied to determine why the human PRTase prefers guanine over xanthine, whereas the Tritrichomonas foetus enzyme exhibits only a slight preference. We analyze this problem with the aid of standard MD simulations, as well as constant-pH MD simulations. Comparison of results of the two approaches reveals substantial differences, e.g. several Asp and Glu residues in the parasite enzyme, and one Glu residue in the human enzyme, are predicted to be permanently or frequently protonated during constant-pH simulations, whereas standard MD simulations assume that these residues are always ionized. Most interesting is the observation of a large conformational change, leading to tighter binding of the ligand, observed in constant-pH MD simulations of the parasite PRTase complexed with XMP, and lack of such a change in the human enzyme complexed with XMP.
Keywords: Ionization states of functional groups, substrate tautomerism, chemotherapy, standard and constant-pH molecular dynamics.
Current Pharmaceutical Design
Title:Resolving Differences in Substrate Specificities between Human and Parasite Phosphoribosyltransferases via Analysis of Functional Groups of Substrates and Receptors
Volume: 19 Issue: 23
Author(s): Zofia Gasik, David Shugar and Jan M. Antosiewicz
Affiliation:
Keywords: Ionization states of functional groups, substrate tautomerism, chemotherapy, standard and constant-pH molecular dynamics.
Abstract: We herein review experimental and theoretical approaches widely applied to delineation of the differences in substrate specificities between human and parasite phosphoribosyltransferases (PRTases), the latter of which are key targets for treatment of diseases caused by parasites. Standard Molecular Dynamics (MD) simulations have been applied to determine why the human PRTase prefers guanine over xanthine, whereas the Tritrichomonas foetus enzyme exhibits only a slight preference. We analyze this problem with the aid of standard MD simulations, as well as constant-pH MD simulations. Comparison of results of the two approaches reveals substantial differences, e.g. several Asp and Glu residues in the parasite enzyme, and one Glu residue in the human enzyme, are predicted to be permanently or frequently protonated during constant-pH simulations, whereas standard MD simulations assume that these residues are always ionized. Most interesting is the observation of a large conformational change, leading to tighter binding of the ligand, observed in constant-pH MD simulations of the parasite PRTase complexed with XMP, and lack of such a change in the human enzyme complexed with XMP.
Export Options
About this article
Cite this article as:
Gasik Zofia, Shugar David and Antosiewicz Jan M., Resolving Differences in Substrate Specificities between Human and Parasite Phosphoribosyltransferases via Analysis of Functional Groups of Substrates and Receptors, Current Pharmaceutical Design 2013; 19 (23) . https://dx.doi.org/10.2174/1381612811319230007
DOI https://dx.doi.org/10.2174/1381612811319230007 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Orofacial Pain and Mastication in Dementia
Current Alzheimer Research Synthesis and Evaluation of Phenyliminoindolin-Containing Phenylacetamide Derivatives with the Antidepressant and Anticonvulsant Effects
Medicinal Chemistry The Therapeutic Potential of Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS: A Combination Approach with HAART
Current HIV Research Editorial (Thematic Issue: Targeting Phosphodiesterases (PDEs) for Treatment of CNS Diseases)
Current Pharmaceutical Design Conventional and New Antiepileptic Drugs on Vitamin D and Bone Health: What We Know to Date?
Current Clinical Pharmacology Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings
CNS & Neurological Disorders - Drug Targets Roles of Orexins and Orexin Receptors in Central Regulation of Feeding Behavior and Energy Homeostasis
CNS & Neurological Disorders - Drug Targets Gabapentin and Pregabalin for the Acute Post-operative Pain Management. A Systematic-narrative Review of the Recent Clinical Evidences
Current Drug Targets Targeting Epigenetics in Nervous System Disease
CNS & Neurological Disorders - Drug Targets GABAergic Pharmacotherapy in the Treatment of Motor Disorders of the Central Nervous System
Current Pharmaceutical Design Non-Amyloid PET Imaging Biomarkers for Neurodegeneration: Focus on Tau, Alpha-Synuclein and Neuroinflammation
Current Alzheimer Research Computational Peptidology: A New and Promising Approach to Therapeutic Peptide Design
Current Medicinal Chemistry The Fate of Nanocarriers As Nanomedicines In Vivo: Important Considerations and Biological Barriers to Overcome
Current Medicinal Chemistry Chest Pain in Children
Current Pediatric Reviews Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Diagnosis and Therapeutic Approaches to Transthyretin Amyloidosis
Current Medicinal Chemistry Intracerebral Hemorrhage and Diabetes Mellitus: Blood-Brain Barrier Disruption, Pathophysiology and Cognitive Impairments
CNS & Neurological Disorders - Drug Targets Structure-Based Design, Synthesis and Molecular Modeling Studies of Thiazolyl Urea Derivatives as Novel Anti-Parkinsonian Agents
Medicinal Chemistry Motor and Non-Motor Features of Parkinson’s Disease – A Review of Clinical and Experimental Studies
CNS & Neurological Disorders - Drug Targets Blood-Brain Barrier Alterations in MDX Mouse, An Animal Model of the Duchenne Muscular Dystrophy
Current Neurovascular Research